Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 24, 2026, 2:50 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 25 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Worsening Heart Failure Clear all
Completed Not applicable Interventional Results available

Danger Signs in Heart Failure- Effects of Video Education

NCT03657459
View directory record Official record
Conditions
Heart Failure; With Decompensation
Interventions
Danger Signs of Heart Failure Videos
Behavioral
Lead sponsor
The Cleveland Clinic
Other
Eligibility
18 Years and older
Enrollment
746 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
8
States / cities
Macon, Georgia • Cleveland, Ohio • Garfield Heights, Ohio + 4 more
Source: ClinicalTrials.gov public record
Updated May 6, 2025 · Synced Jul 24, 2026, 2:50 AM EDT
Terminated Phase 4 Interventional

Dopamine in Acute Decompensated Heart Failure II

NCT01060293
View directory record Official record
Conditions
Acute Decompensated Heart Failure
Interventions
High-dose furosemide, Low-dose furosemide, Low-dose furosemide combined with low-dose dopamine
Drug
Lead sponsor
Larissa University Hospital
Other
Eligibility
18 Years and older
Enrollment
161 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
2
States / cities
Atlanta, Georgia • Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 10, 2013 · Synced Jul 24, 2026, 2:50 AM EDT
Suspended Phase 2 Interventional

CRF2 Agonist for the Treatment of Worsening Heart Failure

NCT06815471
View directory record Official record
Conditions
Worsening Heart Failure
Interventions
COR-1167, Placebo
Drug
Lead sponsor
Corteria Pharmaceuticals
Industry
Eligibility
18 Years to 85 Years
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
7
States / cities
Indianapolis, Indiana • Detroit, Michigan • Greensboro, North Carolina + 3 more
Source: ClinicalTrials.gov public record
Updated Jul 21, 2026 · Synced Jul 24, 2026, 2:50 AM EDT
Completed Phase 3 Interventional

Randomized, Double-Blind, Placebo Controlled Study of the Short Term Clinical Effects of Tolvaptan in Patients Hospitalized for Worsening Heart Failure With Challenging Volume Management

NCT01584557
View directory record Official record
Conditions
Heart Failure
Interventions
Tolvaptan or Samsca, placebo or sugar pill
Drug
Lead sponsor
Cardiovascular Clinical Sciences Inc
Industry
Eligibility
18 Years and older
Enrollment
250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
37
States / cities
Birmingham, Alabama • Huntsville, Alabama • Los Angeles, California + 34 more
Source: ClinicalTrials.gov public record
Updated Sep 26, 2016 · Synced Jul 24, 2026, 2:50 AM EDT
Terminated Phase 2 Interventional Results available

A Study of LY3540378 in Participants With Worsening Chronic Heart Failure With Preserved Ejection Fraction (HFpEF)

NCT05592275
View directory record Official record
Conditions
Heart Failure, Heart Failure With Preserved Ejection Fraction
Interventions
LY3540378, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
332 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
22
States / cities
Tucson, Arizona • Covina, California • Northridge, California + 18 more
Source: ClinicalTrials.gov public record
Updated Feb 4, 2026 · Synced Jul 24, 2026, 2:50 AM EDT
Completed Phase 2 Interventional Results available

Phase IIb Safety and Efficacy Study of Four Dose Regimens of BAY1021189 in Patients With Heart Failure With Reduced Ejection Fraction Suffering From Worsening Chronic Heart Failure (SOCRATES-REDUCED)

NCT01951625
View directory record Official record
Conditions
Heart Failure
Interventions
Vericiguat (BAY1021189) (1.25 mg), Vericiguat (BAY1021189) (5 mg), Placebo
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
456 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
18
States / cities
Fountain Valley, California • Wilmington, Delaware • Fort Lauderdale, Florida + 15 more
Source: ClinicalTrials.gov public record
Updated Mar 24, 2021 · Synced Jul 24, 2026, 2:50 AM EDT
Withdrawn Not applicable Interventional

Effectiveness of Outpatient Intravenous Diuretic Therapy for Treatment of Worsening Heart Failure (OUTPATIENT-WHF)

NCT05704595
View directory record Official record
Conditions
Heart Failure
Interventions
Initial outpatient management strategy, including outpatient IV diuretics in clinic, Initial hospitalization-based management strategy
Other
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 26, 2025 · Synced Jul 24, 2026, 2:50 AM EDT
Completed Phase 3 Interventional

EVEREST: Efficacy of Vasopressin Antagonism in hEart failuRE: Outcome Study With Tolvaptan

NCT00071331
View directory record Official record
Conditions
Congestive Heart Failure
Interventions
Tolvaptan
Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
18 Years and older
Enrollment
3,600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2006
U.S. locations
161
States / cities
Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 131 more
Source: ClinicalTrials.gov public record
Updated May 2, 2012 · Synced Jul 24, 2026, 2:50 AM EDT
Completed Phase 2 Interventional Results available

Phase IIb Safety and Efficacy Study of Different Oral Doses of BAY94-8862 in Subjects With Worsening Chronic Heart Failure and Left Ventricular Systolic Dysfunction and Either Type 2 Diabetes Mellitus With or Without Chronic Kidney Disease or Chronic Kidney Disease Alone

NCT01807221
View directory record Official record
Conditions
Heart Failure
Interventions
Finerenone (BAY94-8862), Placebo, Inspra (eplerenone)
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
1,066 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
10
States / cities
Birmingham, Alabama • La Jolla, California • Los Angeles, California + 6 more
Source: ClinicalTrials.gov public record
Updated Jul 5, 2021 · Synced Jul 24, 2026, 2:50 AM EDT
Completed Phase 2 Interventional Results available

Phase IIb Safety and Efficacy Study of Four Dose Regimens of BAY1021189 in Patients With Heart Failure and Preserved Ejection Fraction Suffering From Worsening Chronic Heart Failure (SOCRATES-PRESERVED)

NCT01951638
View directory record Official record
Conditions
Heart Failure
Interventions
Vericiguat (BAY1021189) (1.25 mg), Vericiguat (BAY1021189) (5 mg), Placebo
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
477 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
17
States / cities
Fountain Valley, California • Fort Lauderdale, Florida • Naples, Florida + 14 more
Source: ClinicalTrials.gov public record
Updated Mar 15, 2021 · Synced Jul 24, 2026, 2:50 AM EDT
Completed Phase 4 Interventional Results available

Tolvaptan For Worsening Outpatient Heart Failure: Role of Copeptin In Identifying Responders

NCT02476409
View directory record Official record
Conditions
Congestive Heart Failure
Interventions
tolvaptan, Placebo
Drug · Other
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2021
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated May 4, 2022 · Synced Jul 24, 2026, 2:50 AM EDT
Terminated Not applicable Interventional

Ultrafiltration Versus IV Diuretics in Worsening Heart Failure

NCT05318105
View directory record Official record
Conditions
Heart Failure (for Example, Fluid Overload), Heart Failure, Fluid Overload
Interventions
Aquadex Smartflow® System, IV Loop Diuretics
Device · Drug
Lead sponsor
Nuwellis, Inc.
Industry
Eligibility
18 Years and older
Enrollment
167 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
15
States / cities
Tucson, Arizona • Long Beach, California • San Diego, California + 10 more
Source: ClinicalTrials.gov public record
Updated Jun 24, 2026 · Synced Jul 24, 2026, 2:50 AM EDT
Completed Phase 2 Interventional Results available

Avoiding Treatment in the Hospital With Furoscix for the Management of Congestion in Heart Failure - A Pilot Study

NCT04593823
View directory record Official record
Conditions
Heart Failure
Interventions
Furoscix Infusor
Combination Product
Lead sponsor
scPharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
18
States / cities
Fairhope, Alabama • Huntsville, Alabama • Hartford, Connecticut + 15 more
Source: ClinicalTrials.gov public record
Updated Jul 31, 2023 · Synced Jul 24, 2026, 2:50 AM EDT
Terminated Phase 3 Interventional Results available

Effect of Sotagliflozin on Cardiovascular Events in Participants With Type 2 Diabetes Post Worsening Heart Failure (SOLOIST-WHF Trial)

NCT03521934
View directory record Official record
Conditions
Heart Failure, Type 2 Diabetes Mellitus
Interventions
Sotagliflozin, Placebo
Drug
Lead sponsor
Lexicon Pharmaceuticals
Industry
Eligibility
18 Years to 85 Years
Enrollment
1,222 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
94
States / cities
Alexander City, Alabama • Cottonwood, Arizona • Little Rock, Arkansas + 83 more
Source: ClinicalTrials.gov public record
Updated Oct 27, 2022 · Synced Jul 24, 2026, 2:50 AM EDT
Completed Phase 3 Interventional Results available

Dapagliflozin Evaluation to Improve the LIVEs of Patients With PReserved Ejection Fraction Heart Failure.

NCT03619213
View directory record Official record
Conditions
Heart Failure With Preserved Ejection Fraction
Interventions
Dapagliflozin, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
40 Years to 130 Years
Enrollment
6,263 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
66
States / cities
Fairhope, Alabama • Mobile, Alabama • Sheffield, Alabama + 57 more
Source: ClinicalTrials.gov public record
Updated Jul 10, 2023 · Synced Jul 24, 2026, 2:50 AM EDT
Completed Phase 2 Interventional

To Evaluate the Safety, Tolerability and Efficacy of R2R01 Combined With SOC as Compared to SOC Alone in Outpatients With Worsening Heart Failure (WHF)

NCT06264310
View directory record Official record
Conditions
Heart Failure, Worsening Heart Failure (WHF)
Interventions
Placebo, R2R01
Drug
Lead sponsor
River 2 Renal Corp.
Industry
Eligibility
18 Years and older
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024
U.S. locations
8
States / cities
Fairhope, Alabama • Fort Meyers, Florida • Hialeah, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Jun 21, 2026 · Synced Jul 24, 2026, 2:50 AM EDT
Completed Phase 3 Interventional Results available

Furoscix Real-World Evaluation for Decreasing Hospital Admissions in Heart Failure

NCT03458325
View directory record Official record
Conditions
Heart Failure
Interventions
Furoscix Infusor
Combination Product
Lead sponsor
scPharmaceuticals, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
8
States / cities
Sylmar, California • Bridgeport, Connecticut • Tampa, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Feb 23, 2023 · Synced Jul 24, 2026, 2:50 AM EDT
Recruiting Phase 4 Interventional

Gator SCALES-WHF: SubCutaneous Administration of Lasix to Eliminate Symptoms of Worsening Heart Failure

NCT06979726
View directory record Official record
Conditions
Heart Failure, Volume Overload
Interventions
Lasix ONYU
Drug
Lead sponsor
University of Florida
Other
Eligibility
18 Years to 80 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Jun 7, 2026 · Synced Jul 24, 2026, 2:50 AM EDT
Completed No phase listed Observational Results available

Surveillance and Alert-based Multiparameter Monitoring to Reduce Worsening Heart Failure Events

NCT04882449
View directory record Official record
Conditions
Heart Failure
Interventions
Bodyport Cardiac Scale
Device
Lead sponsor
Bodyport Inc.
Industry
Eligibility
18 Years and older
Enrollment
329 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
8
States / cities
Boynton Beach, Florida • Panama City, Florida • Gainesville, Georgia + 5 more
Source: ClinicalTrials.gov public record
Updated Feb 9, 2025 · Synced Jul 24, 2026, 2:50 AM EDT
Completed Phase 3 Interventional Results available

Study to Evaluate the Effect of Dapagliflozin on the Incidence of Worsening Heart Failure or Cardiovascular Death in Patients With Chronic Heart Failure

NCT03036124
View directory record Official record
Conditions
Chronic Heart Failure With Reduced Ejection Fraction (HFrEF)
Interventions
Dapagliflozin, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years
Enrollment
4,744 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
86
States / cities
Fairhope, Alabama • Mobile, Alabama • Sheffield, Alabama + 74 more
Source: ClinicalTrials.gov public record
Updated Aug 31, 2020 · Synced Jul 24, 2026, 2:50 AM EDT
Recruiting Not applicable Interventional

Feasibility of the SCD in Cardiorenal Syndrome Patients Awaiting LVAD

NCT03836482
View directory record Official record
Conditions
Acute on Chronic Systolic Congestive Heart Failure, Cardiorenal Syndrome
Interventions
Selective Cytopheretic Device
Device
Lead sponsor
SeaStar Medical
Industry
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Mar 30, 2026 · Synced Jul 24, 2026, 2:50 AM EDT
Suspended Not applicable Interventional

SCD for CRS in Congestive Heart Failure (CHF) (No Left Ventricular Assist Device)

NCT04589065
View directory record Official record
Conditions
Heart Failure, Chronic Systolic Heart Failure, Renal Failure, Cardiorenal Syndrome
Interventions
Selective Cytopheretic Device
Device
Lead sponsor
Lenar Yessayan
Other
Eligibility
21 Years to 70 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Sep 26, 2024 · Synced Jul 24, 2026, 2:50 AM EDT
Terminated Phase 2 Interventional Results available

Safety, Tolerability and Pharmacodynamic Activity of Sotagliflozin in Hemodynamically Stable Participants With Worsening Heart Failure

NCT03292653
View directory record Official record
Conditions
Cardiac Failure Aggravated
Interventions
Sotagliflozin, Placebo
Drug
Lead sponsor
Lexicon Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
4
States / cities
La Jolla, California • New Haven, Connecticut • Rochester, Minnesota + 1 more
Source: ClinicalTrials.gov public record
Updated May 10, 2021 · Synced Jul 24, 2026, 2:50 AM EDT
Completed Phase 3 Interventional Results available

Changes in NT-proBNP, Safety, and Tolerability in HFpEF Patients With a WHF Event (HFpEF Decompensation) Who Have Been Stabilized and Initiated at the Time of or Within 30 Days Post-decompensation (PARAGLIDE-HF)

NCT03988634
View directory record Official record
Conditions
Heart Failure With Preserved Ejection Fraction (HFpEF)
Interventions
sacubitril/valsartan, valsartan, sacubitril/valsartan matching placebo, valsartan matching placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 99 Years
Enrollment
467 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
87
States / cities
Irvine, California • Long Beach, California • Los Angeles, California + 77 more
Source: ClinicalTrials.gov public record
Updated Mar 5, 2025 · Synced Jul 24, 2026, 2:50 AM EDT